Data on Novartis' Lucentis - Analyst Blog

By
A A A

Novartis ( NVS ) presented encouraging new data on its ophthalmology drug Lucentis at the European Society of Retina Specialists (EURETINA) in Germany.

Lucentis is approved for wet age-related macular degeneration (AMD) in over 100 countries. It is also approved for the treatment of visual impairment due to diabetic macular edema (DME) and macular edema secondary to branch- and central-retinal vein occlusion (BRVO and CRVO), and choroidal neovascularization secondary to pathologic myopia (myopic CNV).

The data observed in the phase III study, RADIANCE, showed that Lucentis was superior to current standard of care and improved mean visual acuity by around 14 letters at one year with a median of two injections.

Additionally, the data from various trials indicate that early treatment initiation with Lucentis will result in better vision gains in DME patients.

We note that Novartis has a collaboration agreement with Roche's ( RHHBY ) Genentech for Lucentis.

While Roche holds the commercial rights of Lucentis in the U.S., Novartis holds the rights to develop and market Lucentis outside the U.S.

We remind investors that Novartis also pays royalties to Roche on net Lucentis sales outside the U.S.

Lucentis, one of the key drivers of revenue growth for Novartis in 2012, generated sales of $1.2 billion in 1H13, up 1% year over year.

In Jul 2013, Lucentis was approved to treat patients with visual impairment due to CNV, secondary to myopic CNV in Europe as well.

Label expansion for the additional indication will further boost sales of the drug, which bodes well for both Novartis and Roche.

Novartis currently carries a Zacks Rank #3 (Hold). Right now, Bayer ( BAYRY ) and Novo Nordisk ( NVO ) look attractive with a Zacks Rank #2 (Buy).



BAYER A G -ADR (BAYRY): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

ROCHE HLDG LTD (RHHBY): Get Free Report

VALEANT PHARMA (VRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AMD , BAYRY , NVO , NVS , RHHBY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

THE COST OF HOUSE FLIPPING
THE COST OF HOUSE FLIPPING          

Stocks

Referenced

84%
50%
100%

Most Active by Volume

83,946,369
  • $16.40 ▼ 1.20%
65,919,147
  • $102.99 ▲ 0.51%
63,004,409
  • $42 ▲ 4.53%
42,618,740
  • $7.93 ▼ 2.94%
41,388,613
  • $78.37 ▼ 0.41%
40,438,996
  • $3.81 ▲ 14.76%
39,835,674
  • $12.32 ▲ 2.41%
38,147,728
  • $12.83 ▼ 2.80%
As of 10/22/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com